Arrowhead Pharmaceuticals Inc (ARWR) — Cash Flow Reinvestment Rate

Latest as of September 2025: 4.27x

Arrowhead Pharmaceuticals Inc (ARWR) has a Cash Flow Reinvestment Rate of 4.27x as of September 2025, reinvesting $87.60 Million (capex $7.49 Million plus investments $80.11 Million) from operating cash flow of $20.49 Million. See Arrowhead Pharmaceuticals Inc (ARWR) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

4.27x
(Capex + Investments) / Operating CF

Total Reinvested

$87.60 Million
Capex + Investments

Operating Cash Flow

$20.49 Million
USD

Capital Expenditures

$7.49 Million
USD

Arrowhead Pharmaceuticals Inc Cash Flow Reinvestment Rate (1997–2025)

Historical reinvestment intensity for Arrowhead Pharmaceuticals Inc across 4 annual periods. For the full cash flow conversion analysis, see Arrowhead Pharmaceuticals Inc cash conversion from operations.

Annual Cash Flow Reinvestment Rate for Arrowhead Pharmaceuticals Inc (1997–2025)

Year-by-year capital reinvestment analysis for Arrowhead Pharmaceuticals Inc. See ARWR free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 0.85x $151.96 Million $179.55 Million $22.67 Million ▲ +2.3%
2021 0.83x $141.68 Million $171.22 Million $23.57 Million ▲ +139.6%
2019 0.35x $59.75 Million $173.03 Million $12.00 Million
1997 0.00x $0.00 $4.56K $0.00
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow